Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)

Main Article Content

Arash Mostaghimi
Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts, USA

Melinda Gooderham
SKiN Centre for Dermatology, Peterborough, ON, Canada; Probity Medical Research, Peterborough, ON, Canada; Department of Medicine, Queen’s University, Kingston, ON, Canada

Charles Lynde
Lynde Institute for Dermatology & Lynderm Research Inc., Markham, ON, Canada

Rodney Sinclair
Department of Medicine, University of Melbourne, Melbourne, VIC, Australia; Sinclair Dermatology, Melbourne, VIC, Australia

Brett King
Dermatology Physicians of Connecticut, Fairfield, CT, USA

Maria Hordinsky
Department of Dermatology, University of Minnesota Medical School, Minneapolis, MN, USA

Lidia Rudnicka
Department of Dermatology, Medical University of Warsaw, Warsaw, Poland

Emma Guttman-Yassky
Department of Dermatology and the Laboratory for Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Sebastian Meerwein
AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany

Ahmed Soliman
AbbVie Inc., North Chicago, IL, USA

Xianwei Bu
AbbVie Inc., North Chicago, IL, USA

Chenyang Duan
AbbVie Inc., North Chicago, IL, USA

Tianshuang Wu
AbbVie Inc., North Chicago, IL, USA

Henrique Teixeira
AbbVie Inc., North Chicago, IL, USA

Andreas Lazar
AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany

Thierry Passeron
INSERM U 1065, Centre Méditerranéen de Médecine Moléculaire (C3M), Côte d’Azur University, Nice, France; Department of Dermatology, Centre Hospitalier Universitaire de Nice, Côte d’Azur University, Nice, France

Keywords

alopecia areata, JAK inhibitor, Biologic therapy

References

1. Guttman-Yassy, et al. Lancet. 2021 Jun 5;397(10290):2151–68.

2. Reich, et al. Lancet. 2021 Jun 5;397(10290):2169–81.

Article Sidebar

PDF
Published
2025-11-10
DOI: https://doi.org/10.25251/h3w8px06

Article Details

How to Cite
1.
Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA). J of Skin. 2025;9(6):s664. doi:10.25251/h3w8px06
Issue
Vol. 9 No. 6 (2025): November 2025 Issue
Section
Alopecia
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>